Fort Washington, PA, United States of America

Christopher A Teleha

This inventor holds 25 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Janssen Pharmaceutica Nv, Furiex Pharmaceuticals, Inc., Bristol-Myers Squibb Pharma Company. Active years: 2002-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher A Teleha. Retrieved from https://idiyas.com/inventor/christopher-a-teleha

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 2)

% Patents Active = 56.0

CIPO Patents = 1

EPO Patents = 10 (Patent Applications = 4)

Average Co-Inventor Count = 6.0

ph-index = 8

Forward Citations = 132(Granted Patents)

Location History:

Bear, DE (US) (2002 - 2004)
Spring House, PA (US) (2012 - 2014)
Fort Washington, PA (US) (2007 - 2017)

Company Filing History:

16 out of 2,100

Janssen Pharmaceutica Nv

patents

4 out of 4

Furiex Pharmaceuticals, Inc.

patents

2 out of 234

Bristol-Myers Squibb Pharma Company

patents

4. 1 out of 11

Allergan Holdings Unlimited Company

patents

5. 1 out of 3,737

Bristol-Myers Squibb Compnay

patents

6. 1 out of 1

Forest Tosara Limited

patent

7. 1 out of 263

Mitsubishi Tanabe Pharma Corporation

patents

where one patent can have more than one assignee

Years Active: 2002-2017

Loading Chart...

Areas of Expertise:

TRPM8 Modulators

CB-1 Inverse Agonists

CCR2 Antagonists

SGLT Inhibitors

Cold Menthol Receptor-1

Heterocyclic Esters

Factor Xa Inhibitors

Sulfonamides

Quinoline Derivatives

Fluorinated Pyridines

Enantioselective Processes

Triphenylethylene Derivatives

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9789125 - Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid (2017-10-17),

2. 9464055 - Quinoline derivatives useful as CB-1 inverse agonists (2016-10-11),

3. 9434711 - Sulfonamides as TRPM8 modulators (2016-09-06),

4. 9364489 - Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid (2016-06-14),

5. 9303046 - Process for the preparation of heterocyclic ester derivatives (2016-04-05),

6. 9266835 - Quinoline derivatives useful as CB-1 inverse agonists (2016-02-23),

7. 9150532 - Fused cyclopentyl antagonists of CCR2 (2015-10-06),

8. 9115091 - Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid (2015-08-25),

9. 9090639 - Cold menthol receptor-1 antagonists (2015-07-28),

10. 9056850 - Process for the preparation of compounds useful as inhibitors of SGLT (2015-06-16),

11. 9029352 - Process for the preparation of C-FMS kinase inhibitors (2015-05-12),

12. 8859604 - Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid (2014-10-14),

13. 8809327 - Sulfonamides as TRPM8 modulators (2014-08-19),

14. 8691860 - Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid (2014-04-08),

15. 8680278 - Enantioselective process for preparing a substituted alkanoic acid (2014-03-25),

Title: Christopher A. Teleha: Trailblazer in Pharmaceutical Innovations

Introduction

Christopher A. Teleha, based in Fort Washington, PA, is a prominent inventor with an impressive portfolio of 25 patents. His groundbreaking work primarily focuses on pharmaceutical innovations, particularly in the development of new compounds and processes that can significantly impact the treatment of various medical conditions.

Latest Patents

Among his latest inventions, Teleha has developed novel crystals and processes for creating 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. This invention introduces a new zwitterion form of the compound, which presents exciting possibilities in the pharmaceutical domain. Another noteworthy patent involves the creation of quinoline derivatives, which are positioned as useful CB-1 inverse agonists. These compounds, along with their respective pharmaceutical compositions, are aimed at addressing disorders influenced by the CB-1 receptor, particularly in treating metabolic conditions.

Career Highlights

Teleha's career includes notable tenures at prominent pharmaceutical companies such as Janssen Pharmaceutica and Furiex Pharmaceuticals. His experience in these organizations has allowed him to contribute significantly to the development of innovative medical solutions that can enhance patient care.

Collaborations

Throughout his career, Teleha has collaborated with esteemed colleagues such as Luigi Anzalone and Frank John Villani, Jr. These partnerships have facilitated the exchange of ideas and expertise, driving advancements in their shared field of research and invention.

Conclusion

Christopher A. Teleha's contributions to the field of pharmaceuticals through his innovative inventions and collaborative efforts underscore his role as a significant figure in the industry. With 25 patents to his name, his work continues to pave the way for future advancements and improvements in the treatment of various medical disorders.

Profile summary based on public USPTO records.